Results 41 to 50 of about 72,295 (296)

Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.

The Lancet, 2020
BACKGROUND Head-to-head trials in psoriatic arthritis are helpful in guiding clinical decision making. The EXCEED study evaluated the efficacy and safety of secukinumab versus adalimumab as first-line biological monotherapy for 52 weeks in patients with ...
I. McInnes, F. Behrens, P. Mease, A. Kavanaugh, C. Ritchlin, P. Nash, J. G. Masmitjà, P. Goupille, T. Korotaeva, A. Gottlieb, Ruvie Martin, Kevin Ding, P. Pellet, S. Mpofu, L. Pricop   +14 more
semanticscholar   +1 more source

Efficacy and safety of guselkumab, an anti‐interleukin‐23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double‐blinded, placebo‐ and active comparator–controlled VOYAGE 1 trial

Journal of American Academy of Dermatology, 2017
Background: Guselkumab, an interleukin‐23 blocker, was superior to adalimumab in treating moderate to severe psoriasis in a phase II trial. Objectives: We sought to compare efficacy and safety of guselkumab with adalimumab and placebo in patients with ...
A. Blauvelt, K. Papp, C. Griffiths, B. Randazzo, Y. Wasfi, Yaung-Kaung Shen, Shu Li, A. Kimball   +7 more
semanticscholar   +1 more source

Defining a therapeutic range for adalimumab serum concentrations in the management of pediatric noninfectious uveitis, a step towards personalized treatment

Pediatric Rheumatology Online Journal, 2023
Background Adalimumab is currently considered the most efficacious anti-TNFα agent for childhood noninfectious uveitis (NIU). The objective of this study was to define a therapeutic range for adalimumab trough levels in the treatment of childhood NIU ...
Jo L. Dehoorne, Helena Groth, Emma Carlé, Ilse De Schrijver, Celine Sys, Patricia Delbeke, Elke O. Kreps, Thomas Renson, Carolien Bonroy   +8 more
doaj   +1 more source

Protective Effect of Adalimumab on Diabetic Nephropathy by Regulating TNF-α Signal Pathway

Iranian Journal of Public Health, 2021
Background: To evaluate the inhibitory effect of adalimumab on diabetic nephropathyDN) through animal models. Methods: We carried out the study in Weifang People’s Hospital, Weifang 261041, China in December 2020.
Zhiying Ding, Hongxia Jiang, Yongsong Fan, Guiqin Sun   +3 more
doaj   +1 more source

Systematic review and analysis of evidences on clinical efficacy and cost-effectiveness of biological drugs for the treatment of Ankylosing Spondylitis [PDF]

, 2013
Technology: Infliximab and comparator biological such as adalimumab, etanercept, golimumab. Conditions: Ankylosing spondylitis (AS) Issue: Infliximab is registered to be used in patients with AS.
Péntek, Márta
core   +1 more source

Adalimumab-induced IgA nephropathy

, 2019
Immunoglobulin A nephropathy (IgAN) is the most commonly diagnosed glomerulonephritis worldwide. It is usually idiopathic and may be associated with many other diseases. Recently, biological agents including tumour necrosis factor alpha (TNFα) inhibitors
Wilson, GJ, Ranganathan, D, Singh, AKB, Jeyaruban, AS   +3 more
core   +2 more sources

Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study

Journal of gastroenterology, 2021
This multicenter prospective study (UMIN000019958) aimed to evaluate the usefulness of serum leucin-rich alpha-2 glycoprotein (LRG) levels in monitoring disease activity in inflammatory bowel disease (IBD).
S. Shinzaki, K. Matsuoka, Hiroki Tanaka, F. Takeshima, S. Kato, T. Torisu, Yuki Ohta, Kenji Watanabe, Shiro Nakamura, N. Yoshimura, Taku Kobayashi, A. Shiotani, Fumihito Hirai, S. Hiraoka, M. Watanabe, M. Matsuura, Shohei Nishimoto, S. Mizuno, H. Iijima, T. Takehara, T. Naka, T. Kanai, Takayuki Matsumoto   +22 more
semanticscholar   +1 more source

Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST—Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial

Trials, 2020
Background Juvenile idiopathic arthritis (JIA)-associated uveitis is a chronic paediatric ocular inflammatory condition that can result in visual impairment.
Nisha R. Acharya, Caleb D. Ebert, Nicole K. Kelly, Travis C. Porco, Athimalaipet V. Ramanan, Benjamin F. Arnold, the ADJUST Research Group   +6 more
doaj   +1 more source

Outcome of adalimumab monotherapy in paediatric non-infectious uveitis

Pediatric Rheumatology Online Journal, 2023
Background Adalimumab in combination with other disease-modifying antirheumatic drugs (DMARD) such as methotrexate has a proven efficacy in the management of paediatric non-infectious uveitis.
DA Al-Julandani, NK Bagri, N Tsang, S Clarke, A Upadhyay, C Guly, AV Ramanan   +6 more
doaj   +1 more source

The risk of tuberculosis infection in 410 Saudipatients receiving adalimumab therapy

Annals of Saudi Medicine, 2021
BACKGROUND: Adalimumab is a fully humanized monoclonal antibody inhibitor of tumor necrosis factor-a used to treat various autoimmune disorders. Adalimumab poses a risk for tuberculosis (TB) infection, especially in countries where TB is endemic ...
Abdullah Al-Sohaim, Abdullah Saleh Bawazir, Turki Al-Turki, Eiman Omar Alsafi, Abdullah Al-Roqy, Layla Layqah, Salim Alawi Baharoone   +6 more
doaj   +1 more source